Detalhe da pesquisa
1.
Histotype predicts the curative potential of radiotherapy: the example of ovarian cancers.
Ann Oncol
; 22(2): 341-7, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-20693298
2.
Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study.
Ann Oncol
; 22(11): 2403-2410, 2011 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-21368065
3.
CA 125 normalization with chemotherapy is independently predictive of survival in advanced endometrial cancer.
Gynecol Oncol
; 120(1): 52-5, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-20947152
4.
Preoperative tumor markers at diagnosis in women with malignant mixed müllerian tumors/carcinosarcoma of the uterus.
Int J Gynecol Cancer
; 18(6): 1200-1, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-18217961
5.
Inadequate Rates of BRCA Testing with its Negative Consequences for Women with Epithelial Ovarian Cancer and their Families: an Overview of the Literature.
Clin Oncol (R Coll Radiol)
; 30(8): 472-483, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29735311
6.
Oral etoposide is active against platinum-resistant epithelial ovarian cancer.
J Clin Oncol
; 12(1): 60-3, 1994 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-8270985
7.
Prognostic variables in patients with diffuse large-cell lymphoma treated with MACOP-B.
J Clin Oncol
; 9(2): 220-6, 1991 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-1703227
8.
Ten-year outcome of patients with advanced epithelial ovarian carcinoma treated with cisplatin-based multimodality therapy.
J Clin Oncol
; 10(10): 1561-8, 1992 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-1403035
9.
Small-cell carcinoma of the cervix: fourteen years of experience at a single institution using a combined-modality regimen of involved-field irradiation and platinum-based combination chemotherapy.
J Clin Oncol
; 21(18): 3495-501, 2003 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-12972526
10.
Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study.
J Clin Oncol
; 19(20): 4048-53, 2001 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-11600606
11.
Dose-dense paclitaxel in advanced ovarian cancer.
Clin Oncol (R Coll Radiol)
; 27(1): 40-7, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25455846
12.
A phase II trial of intravenous etoposide (VP-16-213) in epithelial ovarian cancer resistant to cisplatin or carboplatin: clinical and serological evidence of activity.
Int J Gynecol Cancer
; 2(1): 35-40, 1992 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-11576232
13.
Platinum plus cyclophosphamide plus radiotherapy is superior to platinum alone in 'high-risk' epithelial ovarian cancer (residual negative and either stage I or II, grade 3, or stage III, any grade).
Int J Gynecol Cancer
; 5(2): 134-142, 1995 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-11578468
14.
'Moderate-risk' ovarian cancer (stage I, grade 2; stage II, grade 1 or 2) treated with cisplatin chemotherapy (single agent or combination) and pelvi-abdominal irradiation.
Int J Gynecol Cancer
; 4(4): 272-278, 1994 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-11578417
15.
A phase II trial of mitomycin in patients with epithelial ovarian carcinoma resistant to cisplatin or carboplatin.
Am J Clin Oncol
; 13(5): 416-9, 1990 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-2220661
16.
Taxol is active in platinum-resistant endometrial adenocarcinoma.
Am J Clin Oncol
; 19(3): 290-1, 1996 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-8638543
17.
Treatment of advanced epithelial ovarian cancer: past, present and future.
Crit Rev Oncol Hematol
; 20(1-2): 41-59, 1995 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-7576197
18.
[Monozygotic twins and genetic aspects of diabetes]. / Jumeaux monozygotes et aspects génétiques du diabète.
Journ Annu Diabetol Hotel Dieu
; : 121-33, 1985.
Artigo
em Francês
| MEDLINE | ID: mdl-2577957
19.
Carboplatin and paclitaxel for advanced and recurrent cervical carcinoma: the British Columbia Cancer Agency experience.
Gynecol Oncol
; 98(1): 54-8, 2005 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-15904950
20.
A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer.
Int J Gynecol Cancer
; 15(6): 1023-34, 2005.
Artigo
em Inglês
| MEDLINE | ID: mdl-16343178